TORONTO, May 30, 2017 /CNW/ - Cronos Group Inc. (TSX VENTURE: MJN) ("Cronos" or the "Company") is pleased to report the financial results and accompanying management discussion and analysis for the quarter ending March 31, 2017; copies are available on the Company's website (www.thecronosgroup.com) and have been filed with SEDAR (www.sedar.com).
In Q1, Cronos remained focused on the Company's transformation by optimizing operations and building capacity, which resulted in the following highlights from the quarter:
The positive momentum realized in Q1 continued into Q2 with Peace Naturals receiving Good Manufacturing Practice ("GMP") certification and announcing a 315,000 sq. ft. expansion. This expansion includes a state-of-the-art 286,000 sq. ft. building, which is expected to be the world's largest purpose-built indoor cannabis production facility. These advancements will establish Cronos as an international leader by enabling Peace to distribute across the globe while setting the gold standard in quality assurance for medical cannabis.
"Cronos is in the best operational and strategic position since the Company's inception. Q1 brought more than just the formalization of our name change; it ushered in a new chapter in the Company's strategic direction. As a GMP certified operator, we will continue to add value for our shareholders through aggressive, disciplined execution on our pipeline of global expansion opportunities," said Mike Gorenstein, CEO of Cronos.
About Cronos Group
Cronos Group, is a geographically diversified and vertically integrated cannabis company that operates two wholly-owned Licensed Producers ("LPs") regulated within Health Canada's Access to Cannabis for Medical Purposes Regulations (the "ACMPR") and holds a portfolio of minority investments in other Licensed Producers. The Company's flagship LPs, Peace Naturals Project Inc. (Ontario), and In The Zone Produce Ltd. (British Columbia) are collectively situated on over 125 acres of agricultural land and are currently licensed to produce 2,600 kg of cannabis on an annual basis. Cronos Group is focused on building an international iconic brand portfolio, providing patients with compassionate and personalized care, and creating value for our shareholders.
Forward-looking statements
This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation. All information contained herein that is not clearly historical in nature may constitute forward-looking information. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. Except as required by law, Cronos Group disclaims any obligation to update or revise any forward-looking statements. Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by Cronos Group from third parties. Cronos Group believes such information to be accurate but has not independently verified such information.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information, please visit www.thecronosgroup.com.
SOURCE Cronos Group Inc.
Michael Krestell, Investor & Media Relations, TEL: 647-274-3655, E-mail: [email protected]
Also from this source
Share this article